Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:BRNS NASDAQ:CVKD NASDAQ:HCWB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.42-1.6%$2.85$7.96▼$24.15$12.20M0.6315,437 shs203,569 shsBRNSBarinthus Biotherapeutics$1.43-6.9%$0.95$0.64▼$2.92$57.48M-0.8322,652 shs309,057 shsCVKDCadrenal Therapeutics$11.39-4.0%$13.45$5.70▼$22.90$22.44M0.9543,379 shs17,772 shsHCWBHCW Biologics$4.52-4.1%$5.93$3.55▼$100.80$6.54M0.65281,226 shs81,410 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+2.50%-3.53%-7.87%-64.81%-86.77%BRNSBarinthus Biotherapeutics+7.75%+44.34%+73.86%+109.62%+1.99%CVKDCadrenal Therapeutics+6.27%-8.69%-9.60%-29.13%+1,186,999,900.00%HCWBHCW Biologics-1.67%+6.56%-11.13%-33.19%-82.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ABRNSBarinthus Biotherapeutics3.2617 of 5 stars3.55.00.00.01.90.81.3CVKDCadrenal Therapeutics2.9653 of 5 stars3.53.00.00.03.31.70.6HCWBHCW Biologics2.6401 of 5 stars3.52.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ABRNSBarinthus Biotherapeutics 3.00Buy$6.25338.60% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00180.95% UpsideHCWBHCW Biologics 3.00Buy$35.00675.19% UpsideCurrent Analyst Ratings BreakdownLatest HCWB, BRNS, ALVR, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.005/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ABRNSBarinthus Biotherapeutics$14.97M3.84N/AN/A$3.23 per share0.44CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AHCWBHCW Biologics$2.57M2.53N/AN/A($6.08) per share-0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)BRNSBarinthus Biotherapeutics-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)HCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)Latest HCWB, BRNS, ALVR, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.33N/AN/AN/AN/AN/A8/6/2025Q2 2025CVKDCadrenal Therapeutics-$1.60N/AN/AN/AN/AN/A5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78BRNSBarinthus BiotherapeuticsN/A9.189.18CVKDCadrenal TherapeuticsN/A4.324.32HCWBHCW BiologicsN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%BRNSBarinthus Biotherapeutics25.20%CVKDCadrenal Therapeutics7.92%HCWBHCW Biologics2.96%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%BRNSBarinthus Biotherapeutics10.70%CVKDCadrenal Therapeutics48.62%HCWBHCW Biologics42.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableBRNSBarinthus Biotherapeutics10740.34 million36.02 millionN/ACVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionableHCWBHCW Biologics401.44 million825,000Not OptionableHCWB, BRNS, ALVR, and CVKD HeadlinesRecent News About These CompaniesHCW Biologics Inc News (HCWB) - Investing.comJuly 2, 2025 | investing.comInsiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9mJuly 2, 2025 | uk.finance.yahoo.comHCW Biologics Completes Warrant Exercise with ArmisticeJuly 1, 2025 | tipranks.comHCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid TumorsJune 27, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | finanznachrichten.deHCW Biologics Inc. Regains Compliance with Nasdaq Listing RequirementsJune 26, 2025 | quiverquant.comQHCW Biologics Regains Nasdaq Compliance as of June 2025June 26, 2025 | tipranks.comHCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | globenewswire.comHCW Biologics and WY Biotech Finalize Licensing Agreement for HCW11-006, Marking Strategic Development PartnershipJune 6, 2025 | nasdaq.comHCW Biologics Meets Nasdaq Listing Requirements in May 2025June 5, 2025 | tipranks.comHCW Biologics Sinks on Alliance with WY BiotechJune 4, 2025 | baystreet.caHCW Biologics Secures Licensing Agreement with WY BiotechJune 4, 2025 | msn.comHCW Biologics Completes Deliverable and Solidifies License Agreement with WY BiotechJune 4, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Reports First Quarter 2025 Business Highlights and Financial ResultsMay 16, 2025 | finanznachrichten.deHCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trialMay 16, 2025 | fiercebiotech.comFHCW Biologics presents novel CAR-T cell enhancerMay 15, 2025 | uk.investing.comHCW Biologics Inc. Unveils Innovative HCW9206 Fusion Protein at AAI 2025, Promising Enhanced CAR-T Therapy Efficacy and Cost ReductionMay 15, 2025 | nasdaq.comHCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership TalksMay 15, 2025 | nasdaq.comHCW Biologics, Inc.May 15, 2025 | cnn.comHCW Biologics Reports First Quarter 2025 Business Highlights and Financial ResultsMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCWB, BRNS, ALVR, and CVKD Company DescriptionsAlloVir NASDAQ:ALVR$2.42 -0.04 (-1.63%) As of 07/17/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Barinthus Biotherapeutics NASDAQ:BRNS$1.42 -0.11 (-6.86%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Cadrenal Therapeutics NASDAQ:CVKD$11.39 -0.48 (-4.04%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.HCW Biologics NASDAQ:HCWB$4.51 -0.20 (-4.14%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
